Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

December 27, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

April 30, 2022

Conditions

Highly Sensitized Patients on Waiting List for Kidney Transplantation

Interventions

DRUG

Inebilizumab

Infusion of Inebilizumab

DRUG

VIB4920

Infusion of VIB4920

DRUG

Inebilzumab+VIB4920

Infusion of Inebilizumab and VIB4920

Trial Locations (2)

Pennsylvania Reserach Site, Bethlehem

Reserach Site California, San Diego